Information Provided By:
Fly News Breaks for March 6, 2019
Mar 6, 2019 | 12:57 EDT
Evercore ISI analyst Joshua Schimmer upgraded Alnylam to Outperform from In Line and raised his price target to $110 from $87. In a research note to investors, Schimmer says he has been considering an upgrade for a few weeks, and notes that it is not due to this morning's announcement of positive givosiran Phase 3 Envision topline results, nor is it timed to the ongoing Onpattro launch as near-term consensus numbers may be a "little" aggressive. Instead, he says his constructive view is more about the modularity of Alnylam's RNai 'bioengineering" platform and that the company is in a small group of companies positioned for sustainable growth.
News For ALNY From the Last 2 Days
There are no results for your query ALNY